MoertelC.G.,
LefkopouloM.,
LipsitzS.,
HahnR.G.,
KlaassenD.:
Streptozocin-doxorubicin, streptozocin-fluorouracil or
chlorozotocin in the treatment of advanced islet cell
carcinoma.N Engl J Med, 326:
519–523, 1992.
2.
KulkeM.H.,
SiuL.L.,
TepperJ.E.,
FisherG.,
JaffeD.,
HallerD.G.,
EllisL.M.,
BenedettiJ.K.,
BergslandE.K.,
HobdayT.J.,
Van CutsemE.,
PingpankJ.,
ObergK.,
CohenS.J.,
PosnerM.C.,
YaoJ.C.:
Future directions in the treatment of neuroendocrine tumors:
consensus report of the National Cancer Institute neuroendocrine tumor
clinical trials planning meeting.J Clin Oncol, 29:
934–943, 2011.
Della
TorreS.,
ProcopioG.,
FusiA.,
CatenaL.,
FerrariL.,
NovaP.,
DenaroA.,
BichisaoE.,
BajettaE.:
Current treatments of neuroendocrine tumors role of
biotherapy and chemotherapy.Tumori, 89:
111–116, 2003.
5.
RaymondE.,
DahanL.,
RaoulJ.L.,
BangY.J.,
BorbathI.,
Lombard-BohasC.,
ValleJ.,
MetrakosP.,
SmithD.,
VinikA.,
ChenJ.S.,
HörschD.,
HammelP.,
WiedenmannB.,
Van CutsemE.,
PatynaS.,
LuD.R.,
BlanckmeisterC.,
ChaoR.,
RuszniewskiP.:
Sunitinib malate for the treatment of pancreatic
neuroendocrine tumors.N Engl J Med, 364:
501–513, 2011.
6.
Yao JC, Shah MH, Ito T, Bohas CL,
Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG,
Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K;
RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study
Group: Everolimus for advanced pancreatic
neuroendocrine tumors.N Engl J Med, 364:
514–523, 2011.
